These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36371988)

  • 1. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition.
    Shi X; Wang M; Zhang Y; Guo X; Liu M; Zhou Z; Zhao Y; He R; Gao Y; Liu Y; Pan S; Zhou M; Zhao C; Yin T; Li X; Wang H; Yang J; Zhu F; Li M; Qin R
    EBioMedicine; 2022 Dec; 86():104352. PubMed ID: 36371988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
    Xu J; Liu S; Yang X; Cao S; Zhou Y
    Life Sci; 2020 Dec; 263():118523. PubMed ID: 33039386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α.
    Yan B; Jiang Z; Cheng L; Chen K; Zhou C; Sun L; Qian W; Li J; Cao J; Xu Q; Ma Q; Lei J
    Exp Cell Res; 2018 Oct; 371(1):63-71. PubMed ID: 30056064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
    Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
    Xu Z; Pang TCY; Liu AC; Pothula SP; Mekapogu AR; Perera CJ; Murakami T; Goldstein D; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2020 May; 122(10):1486-1495. PubMed ID: 32203220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
    Pothula SP; Xu Z; Goldstein D; Biankin AV; Pirola RC; Wilson JS; Apte MV
    Br J Cancer; 2016 Feb; 114(3):269-80. PubMed ID: 26766740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
    Delitto D; Zhang D; Han S; Black BS; Knowlton AE; Vlada AC; Sarosi GA; Behrns KE; Thomas RM; Lu X; Liu C; George TJ; Hughes SJ; Wallet SM; Trevino JG
    Clin Cancer Res; 2016 Apr; 22(7):1787-99. PubMed ID: 26667487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
    Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
    Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
    Zhang Z; Guo Y; Chen M; Chen F; Liu B; Shen C
    Inflammopharmacology; 2021 Oct; 29(5):1587-1601. PubMed ID: 34322786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrin α6β4 Promotes Autocrine Epidermal Growth Factor Receptor (EGFR) Signaling to Stimulate Migration and Invasion toward Hepatocyte Growth Factor (HGF).
    Carpenter BL; Chen M; Knifley T; Davis KA; Harrison SMW; Stewart RL; O'Connor KL
    J Biol Chem; 2015 Nov; 290(45):27228-27238. PubMed ID: 26381405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
    Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
    J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway.
    Ide T; Kitajima Y; Miyoshi A; Ohtsuka T; Mitsuno M; Ohtaka K; Koga Y; Miyazaki K
    Int J Cancer; 2006 Dec; 119(12):2750-9. PubMed ID: 16998831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.
    Patel MB; Pothula SP; Xu Z; Lee AK; Goldstein D; Pirola RC; Apte MV; Wilson JS
    Carcinogenesis; 2014 Aug; 35(8):1891-900. PubMed ID: 24876152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
    Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
    Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.